Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-05-07 08:31:39

CHESTERBROOK, Pa., May 7, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at...

2014-05-05 08:27:27

1Q 2014 Net Revenues Increased 34% Over 1Q 2013 to $88.5 Million on Acquisition Growth and Launch Momentum for STENDRA and XIAFLEX in Peyronie's Disease CHESTERBROOK, Pa., May 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and, as...

2014-05-01 08:33:52

CHESTERBROOK, Pa., May 1, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m....

2014-04-29 20:27:01

Company to Report Full 1Q 2014 Financial Results on Monday, May 5 CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim(®) testosterone gel. Auxilium's revised financial guidance is as follows ($ millions): Revised...

2014-04-28 08:31:12

Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., April 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be presented at...

2014-04-14 12:32:51

Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These...

2014-04-07 08:29:11

STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture...

2014-03-06 08:31:26

LYNBROOK, N.Y., March 6, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update. "2013 was a very productive and momentous year for BioSpecifics as we continued to demonstrate the vast potential of injectable...

2014-03-04 08:31:02

CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET...

2014-02-28 08:24:37

FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues CHESTERBROOK, Pa., Feb. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014. "2013 was...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.